2W9S
Staphylococcus aureus S1:DHFR in complex with trimethoprim
2W9S の概要
エントリーDOI | 10.2210/pdb2w9s/pdb |
関連するPDBエントリー | 2W9T |
分子名称 | DIHYDROFOLATE REDUCTASE TYPE 1 FROM TN4003, GLYCEROL, NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... (5 entities in total) |
機能のキーワード | antibiotic resistance, dhfr, nadp, oxidoreductase, trimethoprim resistance, one-carbon metabolism, methotrexate resistance |
由来する生物種 | STAPHYLOCOCCUS AUREUS |
タンパク質・核酸の鎖数 | 6 |
化学式量合計 | 115536.66 |
構造登録者 | |
主引用文献 | Heaslet, H.,Harris, M.,Fahnoe, K.,Sarver, R.,Putz, H.,Chang, J.,Subramanian, C.,Barreiro, G.,Miller, J.R. Structural Comparison of Chromosomal and Exogenous Dihydrofolate Reductase from Staphylococcus Aureus in Complex with the Potent Inhibitor Trimethoprim. Proteins, 76:706-, 2009 Cited by PubMed Abstract: Dihydrofolate reductase (DHFR) is the enzyme responsible for the NADPH-dependent reduction of 5,6-dihydrofolate to 5,6,7,8-tetrahydrofolate, an essential cofactor in the synthesis of purines, thymidylate, methionine, and other key metabolites. Because of its importance in multiple cellular functions, DHFR has been the subject of much research targeting the enzyme with anticancer, antibacterial, and antimicrobial agents. Clinically used compounds targeting DHFR include methotrexate for the treatment of cancer and diaminopyrimidines (DAPs) such as trimethoprim (TMP) for the treatment of bacterial infections. DAP inhibitors of DHFR have been used clinically for >30 years and resistance to these agents has become widespread. Methicillin-resistant Staphylococcus aureus (MRSA), the causative agent of many serious nosocomial and community acquired infections, and other gram-positive organisms can show resistance to DAPs through mutation of the chromosomal gene or acquisition of an alternative DHFR termed "S1 DHFR." To develop new therapies for health threats such as MRSA, it is important to understand the molecular basis of DAP resistance. Here, we report the crystal structure of the wild-type chromosomal DHFR from S. aureus in complex with NADPH and TMP. We have also solved the structure of the exogenous, TMP resistant S1 DHFR, apo and in complex with TMP. The structural and thermodynamic data point to important molecular differences between the two enzymes that lead to dramatically reduced affinity of DAPs to S1 DHFR. These differences in enzyme binding affinity translate into reduced antibacterial activity against strains of S. aureus that express S1 DHFR. PubMed: 19280600DOI: 10.1002/PROT.22383 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.8 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード